Program
mirdametinib
Also written as “Mirdametinib”, “PD-0325901” and “Mirdametinib (MEK Inhibitor)”.
Its studies are mostly in Neurofibroma, Plexiform · Melanoma · Carcinoma, Non-Small-Cell Lung, led by 3 companies.
Drug pageMirdametinib: every studyAll 27 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Merck KGaA, Darmstadt, Germanyits history only | 64 open or running | phase 2since Apr 12, 2019 | Apr 12, 2019 | Nov 27, 2026phase 1 · NCT06997276 |
| Pfizer | 20 open or running | phase 2since Sep 2, 2005 | Sep 2, 2005 | none ahead |
| BeOne Medicinesits history only | 10 open or running | phase 1since Apr 3, 2019 | Apr 3, 2019 | none ahead |
Also a collaborator on its studies: SpringWorks Therapeutics.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Pfizer only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
- Sep 2, 2005First studies: 2 phase 2 studiesFirst studyNCT00147550, NCT00174369
- Dec 9, 2019Named mirdametinibINNProposed as its International Nonproprietary Name in WHO's List 122 · before, PD-0325901
TargetBeta
“Dual specificity mitogen-activated protein kinase kinase 1 inhibitor; Dual specificity mitogen-activated protein kinase kinase 2 inhibitor”ChEMBL 37, by rule
Other programs on the same two targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| cobimetinibrule | Hoffmann-La Roche | phase 3 | 38 |
| pimasertibrule | Merck KGaA, Darmstadt, Germany | phase 2 | 13 |
| polfurmetinib | Pfizer | phase 1 | 3 |
Studies
All 2 Pfizer leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT00174369Carcinoma, Non-Small-Cell Lung · United States | 2 | Terminated | Jun 2007 | 34 |
| NCT00147550Melanoma · United States | 2 | Terminated | May 2007 | 79 |
How it is read
Names in the registry
- “Mirdametinib”, 2 entries
- “PD-0325901”, 2 entries
- “Mirdametinib (MEK Inhibitor)”, 1 entry
- “Mirdametinib (PD-0325901) oral capsule or dispersible tablet”, 1 entry
- “Mirdametinib 2mg”, 1 entry
Conditions, from the studies’ own filings
- Neurofibroma, Plexiform, 2 studies
- Melanoma, 1 study
- Carcinoma, Non-Small-Cell Lung, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.